YELIVA – ABC294640 Trial

Discussion Board › Forums › Clinical Trials › YELIVA – ABC294640 Trial

Tagged: 

Viewing 2 posts - 16 through 17 (of 17 total)
1 2
  • Author
    Posts
  • March 18, 2016 at 12:48 am #91942
    marions
    Moderator

    mikeb…..hello and welcome to our group. I don’t think they set a date for a phase II study as of yet, but it will take some time i.e. months or more.
    As far as I understand it, SK2, is an angiogenesis inhibitor, which inhibits the growth of blood vessels. It does not necessarily kill tumors but instead may prevent tumors from growing. It is not a targeted agent and does not require molecular testing.
    Hugs,
    Marion

    March 17, 2016 at 11:15 pm #12295
    mikeb
    Spectator

    I recently saw this press release for YELIVA – ABC294640 – which is focused on Cholangiocarcinoma.

    http://www.thestreet.com/story/13490212/1/redhill-biopharma-announces-peer-reviewed-publication-demonstrating-therapeutic-potential-of-yeliva-in-cholangiocarcinoma-cancer.html

    Does anyone know if/when a Trial will take place?

    It looks like they have tried initial trial for Lymphoma. Does anyone know any feedback on this trial?

    It seems focused on Sphingosine kinase-2 (SK2) inhibitor. I’m not sure if this is important inhibitor in all Cholangiocarcinoma cases, or if only in sub-set with specific markers?

    Thanks to anyone with info :) mb

  • Author
    Posts
Viewing 2 posts - 16 through 17 (of 17 total)
1 2
  • The forum ‘Clinical Trials’ is closed to new topics and replies.